

WEDNESDAY, MAY 19, 2021 13:00-16:30

## The 2<sup>nd</sup> Tel-Aviv University Inflammatory Bowel Diseases Research Seminar

The zoom link to the seminar is:

<https://us02web.zoom.us/j/85856657201?pwd=NIhROGg1TnlMVXBYai94b1BYV1RzQT09>

- 13:00 INTRODUCTION  
**Nitsan Maharshak**, Head of IBD unit, Tel Aviv Sourasky Medical Center
- 13:10 INTRODUCTION OF SPEAKERS  
**Prof. Uri Gophna**, Shmunis School of Bio-Medicine and Cancer Research, Tel Aviv University
- 13:15 CONFORMATION SENSITIVE TARGETING OF LIPID NANOPARTICLES FOR RNA THERAPEUTICS  
**Dan Peer**  
Vice President for Research and Development, Shmunis School of Bio-Medicine and Cancer Research, Tel Aviv University.
- 13:30 TRANSLATING SCIENCE INTO THE IBD CLINIC  
**IRIS DOTAN**  
Director, Division of Gastroenterology, Rabin Medical Center
- 13:45 IDENTIFYING KEY PATHWAYS OF MUCOSAL HOMEOSTASIS THROUGH PATIENTS WITH MONOGENIC IBD  
**Dror Shouval**  
Institute of Gastroenterology, Nutrition and Liver Diseases, Schneider Children's Medical Center of Israel
- 14:00 TARGETING INFLAMMATION AND THE MICROBIOME WITH DIET IN IBD  
**Arie Levine**  
Director, Pediatric Gastroenterology Unit.  
Wolfson Medical Center
- 14:15 HOST: MICROBIAL INTERACTIONS IN IBD  
**Yael Haberman**  
Pediatric Gastroenterology, Sheba Medical Center and Cincinnati Children's Hospital Medical Center
- 14:30 CANNABIS IN INFLAMMATORY BOWEL DISEASE - 10 YEARS OF RESEARCH  
**Timna Naftali**  
The institute of Gastroenterology and Hepatology, Meir Medical center
- 14:45 MONITORING OF CROHN'S DISEASE IN 2021  
**Shomron Ben-Horin**  
Director, Institute of Gastroenterology, Sheba Medical Center
- 15:00 CANNABIS AS A TREATMENT FOR IBD DISEASES, A LESSON FROM PATIENTS, RANDOMIZED CONTROLLED TRIAL AND MURINE MODELS  
**David (Dedi) Meiri**  
Laboratory of Cancer Biology and Cannabinoid Research, Technion
- 15:15 THE MOLECULAR MECHANISMS THAT UNDERLIE THE IMMUNE BIOLOGY OF ANTI-DRUG ANTIBODY FORMATION FOLLOWING TREATMENT WITH MONOCLONAL ANTIBODIES  
**Yariv Wine**

- Shmunis School of Bio-Medicine and Cancer Research, Tel Aviv University
- 15:30 INTRODUCTION OF STUDENTS AWARDS  
**Vered Padler- Karavani**, Shmunis School of Bio-Medicine and Cancer Research, Tel Aviv University
- 15:35 CD300B MEDIATES MUCOSAL HEALING AND REMISSION IN INFLAMMATORY BOWEL DISEASE  
**Shmulik Avlas**, Clinical Microbiology and Immunology, Sackler School of Medicine, Tel-Aviv University, Israel
- 15:40 GLYCOSYLATION EFFECTS ON BIOLOGICAL THERAPIES  
**Sharon Yehuda**, Shmunis School of Bio-Medicine and Cancer Research, Tel Aviv University
- 15:45 LATEST ADVANCES IN CLINICAL IMAGING OF CROHN'S DISEASE  
**Tim Devling**, iThera-Medical
- 15:50 INTRODUCTION OF KEYNOTE SPEAKER  
**Vered Padler- Karavani**, Shmunis School of Bio-Medicine and Cancer Research, Tel Aviv University
- 15:55 – 16:25  
TIMING OF ANTI-TNF INTRODUCTION AND CHANGE IN DISEASE BEHAVIOR  
TRAJECTORIES IN CROHN'S DISEASE; MECHANISMS AND MORE: LESSONS FROM  
RISK COHORT  
**Subra Kugathasan**  
Scientific Director, Children's Healthcare of Atlanta Combined Center for Pediatric  
Inflammatory Bowel Disease  
Department of Pediatrics, Emory University School of Medicine
- 16:20 CLOSING REMARKS  
**Nitsan Maharshak**, Head of IBD unit, Tel Aviv Sourasky Medical Center